Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway - Chen, Xiao-cui; Wu, Dan; Wu, Hong-luan; Li, Hui-yuan; Yang, Chen; Su, Hong-yong; Liu, Ze-jian; Huang, Xiao-rong; Lu, Xing; Huang, Li-feng; Zhu, Shao-ping; Pan, Qing-jun; et al. (Lupus science & medicine, 2022)
Keywords: AMP-Activated Protein Kinases - metabolism; AMP-Activated Protein Kinases - pharmacology; Animals; Antidiabetics; Apoptosis; Creatinine; Humans; Inflammation; Kidney - metabolism; Kidneys; Kinases; Laboratory animals; Lipopolysaccharides - metabolism; Lipopolysaccharides - pharmacology; Lipopolysaccharides - therapeutic use; Lupus; Lupus Erythematosus, Systemic; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - drug therapy; Lupus Nephritis; Lupus Nephritis - complications; Lupus Nephritis - drug therapy; Metformin - pharmacology; Metformin - therapeutic use; Mice; Mice, Inbred MRL lpr; Monoclonal antibodies; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Proteins; Signal Transduction - physiology; STAT3 Transcription Factor - metabolism; STAT3 Transcription Factor - pharmacology; STAT3 Transcription Factor - therapeutic use; Therapeutics; Tumor Necrosis Factor-alpha - metabolism; Tumor Necrosis Factor-alpha - pharmacology; Tumor Necrosis Factor-alpha - therapeutic use; Tumor necrosis factor-TNF; United States--US; China; Japan; Lupus Nephritis; Lupus Erythematosus, Systemic; Therapeutics